Project BioShield established steady, guaranteed funding of $560 million per year as a way to create a market incentive for pharmaceutical companies to produce vaccines for which there is no large-scale commercial demand.

As a report published by the Center for a New American Security (CNAS) notes, the initiative sought to mitigate the financial risks and opportunity costs associated with the lengthy development of new drugs: